154 related articles for article (PubMed ID: 23816245)
1. Leflunomide suppresses growth in human medullary thyroid cancer cells.
Alhefdhi A; Burke JF; Redlich A; Kunnimalaiyaan M; Chen H
J Surg Res; 2013 Nov; 185(1):212-6. PubMed ID: 23816245
[TBL] [Abstract][Full Text] [Related]
2. Resveratrol induces Notch2-mediated apoptosis and suppression of neuroendocrine markers in medullary thyroid cancer.
Truong M; Cook MR; Pinchot SN; Kunnimalaiyaan M; Chen H
Ann Surg Oncol; 2011 May; 18(5):1506-11. PubMed ID: 21184191
[TBL] [Abstract][Full Text] [Related]
3. MK-2206 causes growth suppression and reduces neuroendocrine tumor marker production in medullary thyroid cancer through Akt inhibition.
Burke JF; Schlosser L; Harrison AD; Kunnimalaiyaan M; Chen H
Ann Surg Oncol; 2013 Nov; 20(12):3862-8. PubMed ID: 23900743
[TBL] [Abstract][Full Text] [Related]
4. Suberoyl bishydroxamic acid activates notch1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinoma.
Ning L; Jaskula-Sztul R; Kunnimalaiyaan M; Chen H
Ann Surg Oncol; 2008 Sep; 15(9):2600-5. PubMed ID: 18563491
[TBL] [Abstract][Full Text] [Related]
5. Valproic acid activates Notch1 signaling and induces apoptosis in medullary thyroid cancer cells.
Greenblatt DY; Cayo MA; Adler JT; Ning L; Haymart MR; Kunnimalaiyaan M; Chen H
Ann Surg; 2008 Jun; 247(6):1036-40. PubMed ID: 18520232
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002.
Kunnimalaiyaan M; Ndiaye M; Chen H
Surgery; 2006 Dec; 140(6):1009-14; discussion 1014-5. PubMed ID: 17188151
[TBL] [Abstract][Full Text] [Related]
7. Suberoyl bis-hydroxamic acid activates Notch-1 signaling and induces apoptosis in medullary thyroid carcinoma cells.
Ning L; Greenblatt DY; Kunnimalaiyaan M; Chen H
Oncologist; 2008 Feb; 13(2):98-104. PubMed ID: 18305053
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells.
Kunnimalaiyaan M; Vaccaro AM; Ndiaye MA; Chen H
J Biol Chem; 2006 Dec; 281(52):39819-30. PubMed ID: 17090547
[TBL] [Abstract][Full Text] [Related]
9. Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3beta.
Adler JT; Cook M; Luo Y; Pitt SC; Ju J; Li W; Shen B; Kunnimalaiyaan M; Chen H
Mol Cancer Ther; 2009 Apr; 8(4):914-20. PubMed ID: 19372564
[TBL] [Abstract][Full Text] [Related]
10. The role of human achaete-scute homolog-1 in medullary thyroid cancer cells.
Sippel RS; Carpenter JE; Kunnimalaiyaan M; Chen H
Surgery; 2003 Dec; 134(6):866-71; discussion 871-3. PubMed ID: 14668716
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel Raf-1 pathway activator that inhibits gastrointestinal carcinoid cell growth.
Cook MR; Pinchot SN; Jaskula-Sztul R; Luo J; Kunnimalaiyaan M; Chen H
Mol Cancer Ther; 2010 Feb; 9(2):429-37. PubMed ID: 20103603
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2 and lanreotide in the treatment of medullary thyroid cancer: in vitro and in vivo studies.
Vitale G; Lupoli G; Guarrasi R; Colao A; Dicitore A; Gaudenzi G; Misso G; Castellano M; Addeo R; Facchini G; Del Prete S; Caraglia M
J Clin Endocrinol Metab; 2013 Oct; 98(10):E1567-74. PubMed ID: 23884781
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.
Bentzien F; Zuzow M; Heald N; Gibson A; Shi Y; Goon L; Yu P; Engst S; Zhang W; Huang D; Zhao L; Vysotskaia V; Chu F; Bautista R; Cancilla B; Lamb P; Joly AH; Yakes FM
Thyroid; 2013 Dec; 23(12):1569-77. PubMed ID: 23705946
[TBL] [Abstract][Full Text] [Related]
14. Antisurvivin oligonucleotides inhibit growth and induce apoptosis in human medullary thyroid carcinoma cells.
Du ZX; Zhang HY; Gao DX; Wang HQ; Li YJ; Liu GL
Exp Mol Med; 2006 Jun; 38(3):230-40. PubMed ID: 16819281
[TBL] [Abstract][Full Text] [Related]
15. Thiocoraline alters neuroendocrine phenotype and activates the Notch pathway in MTC-TT cell line.
Tesfazghi S; Eide J; Dammalapati A; Korlesky C; Wyche TP; Bugni TS; Chen H; Jaskula-Sztul R
Cancer Med; 2013 Oct; 2(5):734-43. PubMed ID: 24403239
[TBL] [Abstract][Full Text] [Related]
16. Update on medullary thyroid cancer.
Hu MI; Ying AK; Jimenez C
Endocrinol Metab Clin North Am; 2014 Jun; 43(2):423-42. PubMed ID: 24891170
[TBL] [Abstract][Full Text] [Related]
17. Expression of the active Notch1 decreases MTC tumor growth in vivo.
Jaskula-Sztul R; Pisarnturakit P; Landowski M; Chen H; Kunnimalaiyaan M
J Surg Res; 2011 Nov; 171(1):23-7. PubMed ID: 21571316
[TBL] [Abstract][Full Text] [Related]
18. Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives.
Zatelli MC; Piccin D; Tagliati F; Bottoni A; Luchin A; Vignali C; Margutti A; Bondanelli M; Pansini GC; Pelizzo MR; Culler MD; Degli Uberti EC
J Clin Endocrinol Metab; 2006 Jun; 91(6):2218-24. PubMed ID: 16569735
[TBL] [Abstract][Full Text] [Related]
19. Recombinant leukemia inhibitory factor suppresses human medullary thyroid carcinoma cell line xenografts in mice.
Starenki D; Singh NK; Jensen DR; Peterson FC; Park JI
Cancer Lett; 2013 Oct; 339(1):144-51. PubMed ID: 23856028
[TBL] [Abstract][Full Text] [Related]
20. The role of Cdk5 in neuroendocrine thyroid cancer.
Pozo K; Castro-Rivera E; Tan C; Plattner F; Schwach G; Siegl V; Meyer D; Guo A; Gundara J; Mettlach G; Richer E; Guevara JA; Ning L; Gupta A; Hao G; Tsai LH; Sun X; Antich P; Sidhu S; Robinson BG; Chen H; Nwariaku FE; Pfragner R; Richardson JA; Bibb JA
Cancer Cell; 2013 Oct; 24(4):499-511. PubMed ID: 24135281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
